MedWatch

Novo: We want to be to hemophilia, what we are to diabetes

Novo Nordisk does not just focus on treatment, but on disease-care in a larger scope, when the company develops medicine for hemophilia patients. The idea has been lifted from the company’s approach to diabetes medicine.

Foto: Novo Nordisk/PR

In order to break into the market for hemophilia medicine, Novo Nordisk will make use of the same approach the company used to create its position on the diabetes market, says Vice President for Medical and Science, in Haemostasis Global Development, Stephanie Seremitis, who has just taken part in the World Federation of Hemophilia 2012 World Congress held in Paris from July 9-12.

“It’s about having a more comprehensive approach to patients and help them to identify their needs, beyond just finding which products could treat their specific condition. Patients often have bigger needs than just medicine, and Novo has the same obligations to hemophilia patients, as we have to diabetes patients,” Stephanie Seremetis tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier